Full-Time

Head E-Commerce

Deadline 8/29/26
Sanofi

Sanofi

10,001+ employees

Global pharma company; vaccines and R&D

Compensation Overview

$187.5k - $270.8k/yr

Morristown, NJ, USA

In Person

Bachelor's, MBA

Category
Business & Strategy (1)
Required Skills
Data Analysis

Get referred to Sanofi

See people who can refer or advise you

Requirements
  • Demonstrated experience leading B2B e-commerce strategy or digital channel development in a complex, multi-stakeholder environment, with success driving sales growth.
  • A bachelor's degree is required.
  • At least 10 years of progressive experience, including meaningful depth in B2B e-commerce strategy, digital channel development, or digital marketing in a complex commercial environment.
  • A track record of presenting to and engaging with senior executives as a strategic thought partner.
  • Strong knowledge of B2B e-commerce platforms and the product and roadmap development process.
  • Deep understanding of B2B buying dynamics and the interplay between digital and field sales channels in a relationship-driven selling environment.
  • Ability to structure ambiguous problems, synthesize complex data and market dynamics, and deliver clear recommendations.
  • Ability to translate customer insights into commercial strategies and experience improvements focused on retention and growth.
  • Ability to shape priorities and drive alignment across Digital, Commercial, and senior leadership.
  • Ability to use data and performance analytics to drive decisions, build business cases, and track outcomes.
  • Ability to identify and test new ideas in a structured, hypothesis-driven manner.
  • Ability to build high-performing teams, create clarity of purpose, hold people accountable to results, and invest in employee development.
  • Ability to communicate complex concepts through clear written, verbal, and presentation formats.
Responsibilities
  • Own the end-to-end B2B US e-commerce commercial strategy, including the vision, priorities, and multi-year roadmap for customer acquisition, retention, and revenue growth.
  • Act as general manager for the US e-commerce business and develop strategic growth initiatives while partnering with Digital and Customer Experience organizations responsible for technical delivery and engineering.
  • Translate macro trends, competitive dynamics, and customer insights into strategic positions; build investment business cases and present recommendations to VP, SVP, and business-unit-head stakeholders.
  • Identify and evaluate new business models, market expansion opportunities, and innovative channel strategies for digital B2B commerce in healthcare.
  • Develop and oversee e-commerce strategies that deepen customer relationships and reduce churn among healthcare providers, institutional buyers, and other B2B account segments.
  • Identify friction points and opportunities across the digital buying journey and partner with Digital and Marketing to improve customer lifetime value.
  • Define and monitor key performance indicators for platform adoption, customer engagement, digital revenue contribution, and retention, and hold the organization accountable to outcomes.
  • Collaborate with Sales so e-commerce and representative-led channels are complementary and provide a seamless omnichannel customer experience.
  • Monitor emerging B2B e-commerce trends, competitive moves, and adjacent industry practices, particularly in healthcare and life sciences, and translate insights into recommendations.
  • Champion a test-and-learn culture by designing structured pilots and experiments to validate commercial ideas before scaled deployment.
  • Evaluate and recommend technology, partnership, and capability investments to unlock commercial value on the B2B platform.
  • Co-own the platform roadmap with the Digital E-Commerce organization and ensure business priorities are reflected in technology delivery plans.
  • Influence digital-team priorities and resource allocation through relationships, data, and a commercial perspective without direct engineering authority.
  • Serve as the primary commercial interface to the Digital organization, bridging business strategy and platform execution.
  • Drive accountability for User Acceptance Testing and commercial-readiness activities, ensuring new platform capabilities are validated against real customer scenarios before deployment.
  • Lead and develop a team of e-commerce professionals in the Commercial organization, fostering a high-performance culture and supporting career development.
  • Build relationships across Commercial, Digital, Marketing, Customer Experience, Legal, and Finance to align stakeholders and remove execution barriers.
  • Represent the commercial e-commerce function in senior-leadership forums and prepare and deliver executive communications, business reviews, and investment proposals.
  • Partner with Finance and Commercial leadership to develop annual plans, investment cases, and performance-tracking frameworks tied to e-commerce strategy.
Desired Qualifications
  • Management consulting experience in a strategy or commercial practice, with 3–4 years in a consulting role.
  • An MBA or advanced degree, particularly with a focus in business strategy, marketing, or a related field.
  • Industry experience in healthcare, life sciences, medical devices, diagnostics, specialty distribution, or other regulated or relationship-intensive B2B sectors.
  • Experience operating successfully in a matrixed organization, influencing without direct authority, and building coalitions across functions and levels.

Sanofi is a global pharmaceutical and biotechnology company that develops, manufactures, and sells prescription medicines, over-the-counter products, and vaccines. Its products span immunology, oncology, rare diseases, and vaccines, addressing unmet medical needs through a strong focus on research and development. Sanofi's core product model relies on large-scale R&D, strategic partnerships, and licensing to bring new therapies to markets, with revenue generated from product sales and collaborations. The company differentiates itself by leveraging its global reach, diverse portfolio, and emphasis on patient-centric solutions, safety, and quality to navigate regulatory environments in developed and emerging markets. The company’s goal is to improve health outcomes and quality of life for people worldwide by delivering innovative treatments and vaccines that meet unmet medical needs.

Company Size

10,001+

Company Stage

IPO

Headquarters

Paris, France

Founded

1973

Get referred to Sanofi

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Q2 2026 sales rose 17.8%; Dupixent topped €5.2 billion for the quarter.
  • July 30 upgraded 2026 guidance to around 10% sales growth, with higher EPS.
  • August 4 MenQuadfi infant approval widens vaccine reach; Nexviazyme's June phase 3 readout strengthens pipeline.

What critics are saying

  • Dupixent faces tougher H2 2026 comparisons, threatening growth after the €5.2 billion quarter.
  • Cenrifki carries liver injury risk; strict monitoring can slow adoption and invite liability.
  • Dupixent concentration and Regeneron's November 2024 lawsuit threaten Sanofi's core growth engine.

What makes Sanofi unique

  • Dupixent and partnered launch engine generate repeatable immunology cash flows across geographies.
  • Sanofi converted 2026 approvals for Sarclisa Escena, Wayrilz, and Cenrifki into launches.
  • Paulo Fontoura's September 1 R&D mandate centralizes translational science and regulatory execution.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Professional Development Budget

Parental Leave

Company News

Business Wire
Aug 13th, 2026
Epicrispr Biotechnologies Closes $90 Million Oversubscribed Series C Financing to Advance First-in-Class Epigenetic Therapy Toward Pivotal Studies in FSHD

Epicrispr Biotechnologies Closes $90 Million Series C Financing to Advance First-in-Class Epigenetic Therapy Toward Pivotal Studies in FSHD

Morningstar
Aug 12th, 2026
InduPro raises $77M Series B, doses first patient in Phase 1 trial of bispecific ADC for lung cancer

InduPro has closed a $77 million Series B financing round and dosed its first patient in a Phase 1 study of IDP-001, its lead oncology programme. The biotechnology company is developing IDP-001, a bispecific antibody-drug conjugate targeting EGFR and a novel tumour-associated proximity antigen, for treating advanced squamous non-small cell lung cancer and other solid tumours. The Column Group led the financing round, with participation from Vida Ventures, MRL Ventures Fund, Emerson Collective, Euclidean Capital, Solasta Ventures, Sanofi, and Eli Lilly and Company. Proceeds will support Phase 1 clinical development and early proof-of-concept data generation for IDP-001, whilst advancing InduPro's broader preclinical pipeline. InduPro uses a proximity-guided platform to map protein spatial relationships on cell surfaces for discovering selective co-target pairs.

FinancialContent
Jul 24th, 2026
Scribe Therapeutics prices upsized $129M IPO at top of range

Scribe Therapeutics, a clinical-stage biotechnology company developing in vivo CRISPR technologies, has priced its upsized initial public offering at $15.00 per share, the high end of its range. The company is offering 8,580,000 shares, expecting to raise $128.7 million in gross proceeds before fees and expenses. Scribe has also granted underwriters a 30-day option to purchase up to 1,287,000 additional shares. The shares are expected to begin trading on the Nasdaq Global Market on 24 July 2026 under the ticker symbol "SCTX", with the offering closing on 27 July 2026. Additionally, Scribe has agreed to sell 500,000 shares at the same price to Sanofi in a concurrent private placement. Leerink Partners, Goldman Sachs, Guggenheim Securities, and Wells Fargo Securities are serving as joint book-running managers.

Associated Press
Jul 10th, 2026
Sanofi's Sarclisa Escena approved in US as first anticancer drug delivered via on-body injector

The US Food and Drug Administration has approved Sanofi's subcutaneous Sarclisa Escena for treating multiple myeloma, making it the first anticancer treatment administered through an on-body injector. The therapy uses Enable Injections' CirCLIQ device, which delivers the drug automatically with a retractable 30g needle. The approval was supported by the IRAKLIA phase 3 study, which demonstrated that Sarclisa Escena delivered via the on-body injector provided similar efficacy and safety compared to intravenous infusion, with significantly shorter treatment time and fewer infusion-related reactions. The study showed a 71.1% objective response rate in patients with relapsed or refractory multiple myeloma. More than 70,000 patients worldwide have been treated with Sarclisa-based regimens. The on-body injector aims to reduce physical burden on healthcare providers whilst offering patients greater convenience during treatment.

Yahoo Finance
Jul 5th, 2026
Sanofi appoints Paulo Fontoura as R&D chief to accelerate pharma pipeline transformation

Sanofi has appointed Paulo Fontoura as Executive Vice President and Global Head of Research & Development Pharma, effective 1 September. Based in Paris, Fontoura will oversee the company's innovation engine, spanning research, translational medicine, clinical development, and regulatory affairs. He succeeds Dr Houman Ashrafian, who is leaving to pursue new opportunities. Fontoura brings over 25 years of experience across academic medicine, translational science, and pharmaceutical innovation. The appointment comes as Sanofi drives an R&D transformation whilst progressing its pipeline across multiple therapeutic areas. Separately, MacroGenics confirmed it will receive $24.5 million in regulatory milestone payments from Sanofi following FDA accelerated approval of TZIELD to delay decline in endogenous insulin production in children. Sanofi is a global biopharmaceutical company focusing on immunology, rare diseases, and oncology.